{"id":2296,"date":"2011-11-22T17:13:26","date_gmt":"2011-11-23T03:13:26","guid":{"rendered":"http:\/\/www.hawaii.edu\/news\/?p=2296"},"modified":"2021-06-02T11:22:17","modified_gmt":"2021-06-02T21:22:17","slug":"cancer-mutation","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2011\/11\/22\/cancer-mutation\/","title":{"rendered":"Mutation makes anti-cancer protein a tumor booster"},"content":{"rendered":"Reading time: <\/span> 2<\/span> minutes<\/span><\/span>
\"Three
Clockwise from left, researchers Florian Sulzmaier, Maisel Caliva and Joe Ramos<\/figcaption><\/figure>\n

A protein that slows the growth and spread of ovarian cancer can surprisingly enhance tumor formation in kidney cells that carry a certain mutation, according to a new study from the University of Hawaiʻi<\/span> Cancer Center<\/a> that has implications for cancer treatment.<\/p>\n

The H-Ras gene regulates cell division. A cancer-promoting mutation in the gene contributes to the development, proliferation and metastasis of tumors in many human malignancies.<\/p>\n

The protein, called PEA-15<\/abbr>, inhibits tumor cell proliferation and metastasis by opposing H-Ras signals. <\/p>\n

While PEA-15<\/abbr> has shown promising potential for treating ovarian and breast cancer and as a marker of prolonged patient survival in ovarian cancer, it may also trigger tumor growth, suggesting caution in pursuing the use of PEA-15<\/abbr> as an anti-cancer therapeutic. <\/p>\n

The new study—the first to report a pro-cancer growth effect of PEA-15<\/abbr>—was published online November 21 in the journal Oncogene<\/em>.<\/p>\n

\"microscopic
Microscopic photo of a transformed kidney cell<\/figcaption><\/figure>\n

“Our findings reveal a surprising mechanism by which PEA-15<\/abbr> can enhance H-Ras driven transformation of cells, rather than stop it,” said corresponding author Joe W. Ramos<\/strong>, co-director of the 糖心视频<\/abbr> Cancer Center’s Cancer Biology Program. PEA-15<\/abbr> accelerated the rate of tumor formation in mouse kidney epithelial cells containing a Ras mutation both in vitro and in vivo.<\/p>\n

The difference relates to the signaling pathways active in a specific tumor cell, he explained.<\/p>\n

“An interplay of factors determines the fate of a patient,” noted lead author Florian Sulzmaier<\/strong>, a doctoral candidate in the Department of Molecular Biosciences and Bioengineering<\/a>. “PEA-15<\/abbr> might still be worth considering for treatment of certain cancers. However, care should be taken in tumor types that carry Ras mutations that could change the outcome of a therapy.”<\/p>\n

The research team also included 糖心视频<\/abbr> Mānoa research assistants Mohana Valmiki<\/strong> and Maisel Caliva<\/strong>, Assistant Professor Michelle L. Matter<\/strong> and colleagues at the Cancer Institute of New Jersey and Academic Medical Center, University of Amsterdam. <\/p>\n

The study was supported by a grant from the National Institutes of Health National Cancer Institute<\/a> and National Institute of General Medical Sciences<\/a> and the Victoria S. and Bradley Geist Foundation.<\/p>\n

Read the abstract in Nature<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

A cancer inhibitor can also trigger tumor development according to surprising new 糖心视频<\/abbr> Cancer Center findings. <\/p>\n","protected":false},"author":16,"featured_media":2342,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[218,212,158,169,9],"class_list":["post-2296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","tag-cancer","tag-college-of-tropical-agriculture-and-human-resilience","tag-publication","tag-uh-cancer-center","tag-uh-manoa","entry","has-media"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t